Abstract
The epidermal growth factor receptor (EGFr) is one of the most studied molecules as a target for cancer therapy. Over these last few years, several studies attempting to identify predictive biomarkers of treatment response, such as the receptor status or other molecules related to the downstream signalling pathway, have been conducted. However, from a clinical point of view, the information obtained from ex vivo analyses still has various limitations that may be overcome by the combination with molecular imaging technologies which may provide a noninvasive, global, in vivo evaluation of the molecular tumour background. The aim of this review is to report the preclinical results of all positron emission tomography (PET) tracers synthesized until now for in vivo detection of EGFr in cancer. Two classes of PET compounds have been developed: labelled small molecules such as tyrosine kinase inhibitors and labelled monoclonal antibodies. The in vitro and in vivo results of these PET tracers are very different depending on the chemical properties, positron emission radionuclide, or animal models. As a consequence, various critical questions are still open, and the implications of a translation in the clinical setting for EGFr imaging in cancer patients is discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 213-226 |
| Number of pages | 14 |
| Journal | Annals of Oncology |
| Volume | 20 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2009 |
Fingerprint
Keywords
- Colon cancer
- Epidermal growth factor receptor (EGFr)
- Lung cancer
- Monoclonal antibodies
- PET
- Tyrosine kinase inhibitors
ASJC Scopus subject areas
- Oncology
- Hematology
Cite this
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. / Pantaleo, Maria A.; Nannini, M.; Maleddu, A.; Fanti, S.; Nanni, C.; Boschi, S.; Lodi, F.; Nicoletti, G.; Landuzzi, L.; Lollini, P. L.; Biasco, G.
In: Annals of Oncology, Vol. 20, No. 2, 2009, p. 213-226.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer
AU - Pantaleo, Maria A.
AU - Nannini, M.
AU - Maleddu, A.
AU - Fanti, S.
AU - Nanni, C.
AU - Boschi, S.
AU - Lodi, F.
AU - Nicoletti, G.
AU - Landuzzi, L.
AU - Lollini, P. L.
AU - Biasco, G.
PY - 2009
Y1 - 2009
N2 - The epidermal growth factor receptor (EGFr) is one of the most studied molecules as a target for cancer therapy. Over these last few years, several studies attempting to identify predictive biomarkers of treatment response, such as the receptor status or other molecules related to the downstream signalling pathway, have been conducted. However, from a clinical point of view, the information obtained from ex vivo analyses still has various limitations that may be overcome by the combination with molecular imaging technologies which may provide a noninvasive, global, in vivo evaluation of the molecular tumour background. The aim of this review is to report the preclinical results of all positron emission tomography (PET) tracers synthesized until now for in vivo detection of EGFr in cancer. Two classes of PET compounds have been developed: labelled small molecules such as tyrosine kinase inhibitors and labelled monoclonal antibodies. The in vitro and in vivo results of these PET tracers are very different depending on the chemical properties, positron emission radionuclide, or animal models. As a consequence, various critical questions are still open, and the implications of a translation in the clinical setting for EGFr imaging in cancer patients is discussed.
AB - The epidermal growth factor receptor (EGFr) is one of the most studied molecules as a target for cancer therapy. Over these last few years, several studies attempting to identify predictive biomarkers of treatment response, such as the receptor status or other molecules related to the downstream signalling pathway, have been conducted. However, from a clinical point of view, the information obtained from ex vivo analyses still has various limitations that may be overcome by the combination with molecular imaging technologies which may provide a noninvasive, global, in vivo evaluation of the molecular tumour background. The aim of this review is to report the preclinical results of all positron emission tomography (PET) tracers synthesized until now for in vivo detection of EGFr in cancer. Two classes of PET compounds have been developed: labelled small molecules such as tyrosine kinase inhibitors and labelled monoclonal antibodies. The in vitro and in vivo results of these PET tracers are very different depending on the chemical properties, positron emission radionuclide, or animal models. As a consequence, various critical questions are still open, and the implications of a translation in the clinical setting for EGFr imaging in cancer patients is discussed.
KW - Colon cancer
KW - Epidermal growth factor receptor (EGFr)
KW - Lung cancer
KW - Monoclonal antibodies
KW - PET
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=60549084533&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60549084533&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdn625
DO - 10.1093/annonc/mdn625
M3 - Article
C2 - 18842614
AN - SCOPUS:60549084533
VL - 20
SP - 213
EP - 226
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 2
ER -